Glivec and Norvasc drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glivec (imatinib mesylate) and Norvasc (amlodipine besylate). Common drug interactions include decreased appetite among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Glivec and Norvasc. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Glivec?

Glivec has active ingredients of imatinib mesylate. eHealthMe is studying from 17,777 Glivec users. Check the latest studies of Glivec.

What is Norvasc?

Norvasc has active ingredients of amlodipine besylate. It is often used in high blood pressure. eHealthMe is studying from 136,738 Norvasc users. Check the latest studies of Norvasc.



On Jul, 14, 2026

23 people who take Glivec and Norvasc together, and have interactions are studied.

Glivec and Norvasc drug interactions.

What are the common drug interactions of Glivec and Norvasc, by gender? *:

female:

  1. Decreased appetite
  2. Gastrointestinal stromal tumour (a cancer that arises from transformed cells of mesenchymal origin in gastrointestinal tract)
  3. Hypertensive heart disease
  4. Neoplasm recurrence (reoccurrence of tumour)
  5. Vomiting
  6. Blood bilirubin decreased
  7. Dyspepsia (indigestion)
  8. Haematocrit decreased
  9. Haemoglobin decreased
  10. Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)

male:

  1. Anaemia (lack of blood)
  2. Haemoglobin decreased
  3. Red blood cell count decreased
  4. Blood lactate dehydrogenase increased
  5. Cerebral haemorrhage (bleeding within the brain)
  6. Coma (state of unconsciousness lasting more than six hours)
  7. Cough
  8. Diarrhoea
  9. Eyelid oedema (eyelids are swollen and contain excessive fluid)
  10. Flatulence (flatus expelled through the anus)

What are the common drug interactions of Glivec and Norvasc, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Anaemia (lack of blood)
  2. C-reactive protein increased
  3. Cerebral haemorrhage (bleeding within the brain)
  4. Coma (state of unconsciousness lasting more than six hours)
  5. Cough
  6. Diarrhoea
  7. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  8. Eyelid oedema (eyelids are swollen and contain excessive fluid)
  9. Flatulence (flatus expelled through the anus)
  10. Gingival bleeding (bleeding gums)

50-59:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Oliguria (not enough urine)
  3. Pneumonia
  4. Pyrexia (fever)
  5. Rash
  6. Renal disorder (kidney disease)
  7. Sepsis (a severe blood infection that can lead to organ failure and death)
  8. Skin disorder (skin disease)
  9. Staphylococcus test positive
  10. Urticaria (rash of round, red welts on the skin that itch intensely)

60+:

  1. Red blood cell count decreased
  2. Haematocrit decreased
  3. Blood lactate dehydrogenase increased
  4. White blood cell count increased
  5. Back pain
  6. Blood bilirubin decreased
  7. Diabetic nephropathy (diabetic kidney disease)
  8. Dyspepsia (indigestion)
  9. Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
  10. Malignant neoplasm progression (cancer tumour came back)

What are the existing conditions these people have? *

  1. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 19 people, 82.61%
  2. Spinal Osteoarthritis (joint cartilage loss in spine): 4 people, 17.39%
  3. Panic Disorder: 4 people, 17.39%
  4. Gastrointestinal Stromal Tumor: 3 people, 13.04%
  5. Diabetes: 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Glivec and Norvasc?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glivec and Norvasc:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glivec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Norvasc:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glivec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Norvasc and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate and amlodipine besylate (the active ingredients of Glivec and Norvasc, respectively), and Glivec and Norvasc (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: